N/A N=54 Diagnostic

Alpha MSH in Ocular Disease

Advanced Dry Macular Degeneration

Bottom Line

View on ClinicalTrials.gov: NCT03451578 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2022

Primary outcome: Primary: Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Alpha MSH assay (Device)
Age: Adult, Older Adult · 60+ yrs
Sex: All
Sponsor: Duke University
Primary completion: Oct 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay	—	—

Summary

The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.

Eligibility Criteria

Inclusion Criteria

60 years or older
diagnosis of advanced dry macular degeneration with foveal geographic atrophy
limited vision or blindness (20/100 or worse) in that eye
pseudophakia (prior cataract surgery in that eye)

Exclusion Criteria

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03451578). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.